The biotech has named Jamie Coleman its chief commercial officer, per a Monday announcement, putting her in charge of the ...

GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...

About 140,400 obese patients in Massachusetts were prescribed medications like Wegovy and Zepbound in 2024, a 255 percent ...

FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...

Biopharma executives shared their thoughts on the potential impacts of the new administration; Annalee Armstrong recaps JPM ...

An experimental drug called amycretin showed signs it could be more potent than Eli Lilly’s rival Zepbound, though analysts ...

Eli Lilly (NYSE: LLY) has become a beast in healthcare. The excitement surrounding its GLP-1 drugs, Mounjaro and Zepbound, ...

Her doctor prescribed the cheaper, generic version of the weight-loss drug after her insurer refused to cover Zepbound, the ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has ...